{'text': '\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSee discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/8145245\n\nFalse-Positive Results in a Recombinant Severe Acute Respiratory\n\nSyndrome-Associated Coronavirus (SARS-CoV) Nucleocapsid Enzyme-\n\nLinked Immunosorbent Assay Due to HCoV-OC43 a....\n\nArticle\xa0\xa0in\xa0\xa0Journal of Clinical Microbiology · January 2005\n\nDOI: 10.1128/JCM.42.12.5885-5888.2004\xa0·\xa0Source: PubMed\n\nCITATIONS\n\n73\nREADS\n\n433\n\n9 authors, including:\n\nSome of the authors of this publication are also working on these related projects:\n\nmaterials View project\n\nClinical application of MALDI-TOF MS View project\n\nSusanna Kp Lau\n\nThe University of Hong Kong\n\n812 PUBLICATIONS\xa0\xa0\xa026,205 CITATIONS\xa0\xa0\xa0\n\nSEE PROFILE\n\nKwok-Hung Chan\n\nThe University of Hong Kong\n\n744 PUBLICATIONS\xa0\xa0\xa061,364 CITATIONS\xa0\xa0\xa0\n\nSEE PROFILE\n\nJoseph S Malik Peiris\n\nThe University of Hong Kong\n\n1,192 PUBLICATIONS\xa0\xa0\xa0103,687 CITATIONS\xa0\xa0\xa0\n\nSEE PROFILE\n\nRobert B Couch\n\nBaylor College of Medicine\n\n64 PUBLICATIONS\xa0\xa0\xa04,506 CITATIONS\xa0\xa0\xa0\n\nSEE PROFILE\n\nAll content following this page was uploaded by Joseph S Malik Peiris on 25 April 2015.\n\nThe user has requested enhancement of the downloaded file.\n\nhttps://www.researchgate.net/publication/8145245_False-Positive_Results_in_a_Recombinant_Severe_Acute_Respiratory_Syndrome-Associated_Coronavirus_SARS-CoV_Nucleocapsid_Enzyme-Linked_Immunosorbent_Assay_Due_to_HCoV-OC43_and_HCoV-229E_Rectified_by_Wes?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_2&_esc=publicationCoverPdf\nhttps://www.researchgate.net/project/materials-36?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_9&_esc=publicationCoverPdf\nhttps://www.researchgate.net/project/Clinical-application-of-MALDI-TOF-MS?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_9&_esc=publicationCoverPdf\nhttps://www.researchgate.net/?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_1&_esc=publicationCoverPdf\nhttps://www.researchgate.net/profile/Susanna-Lau?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_4&_esc=publicationCoverPdf\nhttps://www.researchgate.net/profile/Susanna-Lau?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_5&_esc=publicationCoverPdf\nhttps://www.researchgate.net/institution/The-University-of-Hong-Kong?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_6&_esc=publicationCoverPdf\nhttps://www.researchgate.net/profile/Susanna-Lau?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_7&_esc=publicationCoverPdf\nhttps://www.researchgate.net/profile/Kwok-Hung-Chan?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_4&_esc=publicationCoverPdf\nhttps://www.researchgate.net/profile/Kwok-Hung-Chan?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_5&_esc=publicationCoverPdf\nhttps://www.researchgate.net/institution/The-University-of-Hong-Kong?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_6&_esc=publicationCoverPdf\nhttps://www.researchgate.net/profile/Kwok-Hung-Chan?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_7&_esc=publicationCoverPdf\nhttps://www.researchgate.net/profile/Joseph-S-Peiris-2?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_4&_esc=publicationCoverPdf\nhttps://www.researchgate.net/profile/Joseph-S-Peiris-2?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_5&_esc=publicationCoverPdf\nhttps://www.researchgate.net/institution/The-University-of-Hong-Kong?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_6&_esc=publicationCoverPdf\nhttps://www.researchgate.net/profile/Joseph-S-Peiris-2?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_7&_esc=publicationCoverPdf\nhttps://www.researchgate.net/profile/Robert-Couch-2?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_4&_esc=publicationCoverPdf\nhttps://www.researchgate.net/profile/Robert-Couch-2?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_5&_esc=publicationCoverPdf\nhttps://www.researchgate.net/institution/Baylor-College-of-Medicine?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_6&_esc=publicationCoverPdf\nhttps://www.researchgate.net/profile/Robert-Couch-2?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_7&_esc=publicationCoverPdf\nhttps://www.researchgate.net/profile/Joseph-S-Peiris-2?enrichId=rgreq-2af56a660bb7036a7b4895f70661ef42-XXX&enrichSource=Y292ZXJQYWdlOzgxNDUyNDU7QVM6MjIyMDAwMzkzMDAzMDExQDE0Mjk5NDA0MjY5NTQ%3D&el=1_x_10&_esc=publicationCoverPdf\n\n\nJOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2004, p. 5885–5888 Vol. 42, No. 12\n0095-1137/04/$08.00�0 DOI: 10.1128/JCM.42.12.5885–5888.2004\nCopyright © 2004, American Society for Microbiology. All Rights Reserved.\n\nFalse-Positive Results in a Recombinant Severe Acute Respiratory\nSyndrome-Associated Coronavirus (SARS-CoV)\nNucleocapsid Enzyme-Linked Immunosorbent\nAssay Due to HCoV-OC43 and HCoV-229E\n\nRectified by Western Blotting\nwith Recombinant SARS-CoV\n\nSpike Polypeptide\nPatrick C. Y. Woo,1 Susanna K. P. Lau,1 Beatrice H. L. Wong,1 Kwok-Hung Chan,1\n\nWai-Ting Hui,1 Grace S. W. Kwan,1 J. S. Malik Peiris,1\nRobert B. Couch,2 and Kwok-Yung Yuen1*\n\nDepartment of Microbiology, The University of Hong Kong, Hong Kong,1 and Department of\nMolecular Virology and Microbiology, Baylor College of\n\nMedicine, Houston, Texas2\n\nReceived 29 March 2004/Returned for modification 9 June 2004/Accepted 21 August 2004\n\nUsing paired serum samples obtained from patients with illness associated with increases in anti-human\ncoronavirus OC43 (HCoV-OC43) or anti-HCoV-229E antibodies, we examined the possibility of false-positive\nresults detected in a recombinant severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-\nCoV) nucleocapsid protein immunoglobulin G enzyme-linked immunosorbent assay (ELISA). Three of the 21\nand 1 of the 7 convalescent-phase serum samples from persons with increases in antibodies against HCoV-\nOC43 and HCoV-229E, respectively, tested positive by the recombinant SARS-CoV nucleocapsid protein-based\nELISA. None of these samples were found to contain a specific antibody in the recombinant SARS-CoV spike\npolypeptide-based Western blot assay.\n\nSevere acute respiratory syndrome (SARS), caused by\nSARS-associated coronavirus (SARS-CoV), has affected 30\ncountries in five continents, with more than 8,000 cases and 750\ndeaths (7–11). As for the detection of antibodies against\nSARS-CoV, at the moment, the most widely used methods are\nantibody detection in acute- and convalescent-phase sera by\nindirect immunofluorescence assay and enzyme-linked immu-\nnosorbent assay (ELISA) using cell culture extracts (4, 8, 10).\nHowever, antibody detection by these methods may be less\nreproducible, more difficult to standardize, and more labor-\nintensive than ELISA-based antibody detection tests using re-\ncombinant antigens. Furthermore, producing the infected cell\nlines for coating the ELISA plates and the slides for indirect\nimmunofluorescence requires cultivation of the SARS-CoV,\nfor which biosafety level 3 laboratory facilities are required.\nSuch facilities are not available in most clinical microbiology\nlaboratories.\n\nELISA-based antibody detection tests using recombinant\nantigens are well known to offer higher reproducibility and to\nbe easier to standardize and less labor-intensive than antibody\ndetection by indirect immunofluorescence assay and ELISA\nusing cell culture extract, and they do not require cultivation of\nthe SARS-CoV (1, 2, 14, 18). Recently, we have reported the\n\nuse of recombinant SARS-CoV nucleocapsid protein ELISA-\nbased antibody tests for serodiagnosis of SARS-CoV pneumo-\nnia and the study of the seroprevalence of nonpneumonic\nSARS-CoV infections (15, 16). In addition, others have also\nreported the use of recombinant-protein-based immunoassays\nfor serodiagnosis of SARS-CoV pneumonia (3, 17). However,\nin our studies, we have also shown that false-positive reactions\nwere detected if the recombinant SARS-CoV nucleocapsid\nprotein-based ELISA was used alone for antibody detection\n(15). In this study, using paired serum samples obtained from\npatients with increases in anti-human CoV OC43 (HCoV-\nOC43) or anti-HCoV-229E antibodies, we examined the pos-\nsibility of false-positive results detected by the recombinant\nSARS-CoV nucleocapsid protein-based ELISA. The impor-\ntance of using Western blot assays, with the nucleocapsid pro-\ntein and spike polypeptide of SARS-CoV, for confirmation was\nalso determined.\n\nPaired serum samples collected from 21 and 7 patients with\nrecent infections by HCoV-OC43 and HCoV-229E, respec-\ntively, were retrieved from the serum bank of the Respiratory\nPathogens Research Unit of the Baylor College of Medicine.\nThe paired serum samples were shown to exhibit significant\nincreases in anti-HCoV-OC43 antibodies by immunoassay or\nin anti-HCoV-229E antibodies in microneutralization tests\nsimilar to those described previously (5, 6).\n\nCloning and purification of His6-tagged recombinant nu-\ncleocapsid protein and optimization of the ELISA for detec-\ntion of immunoglobulin G (IgG) against SARS-CoV were as\n\n* Corresponding author. Mailing address: Department of Microbi-\nology, The University of Hong Kong, University Pathology Building,\nQueen Mary Hospital, Hong Kong. Phone: (852) 28554892. Fax: (852)\n28551241. E-mail: hkumicro@hkucc.hku.hk.\n\n5885\n\n\n\nreported previously (15). ELISA was performed according to\nour previous publications (13, 14) using paired serum samples\n(diluted 1:40) positive for the anti-HCoV-OC43 or anti-\nHCoV-229E antibody. Cloning and purification of the His6-\ntagged recombinant spike polypeptide of SARS-CoV were as\nreported previously (15). Western blot analysis was performed\naccording to our previous publications (14, 15, 18).\n\nThree of the 21 convalescent-phase serum samples, but none\nof the acute-phase serum samples, from patients with recent\nHCoV-OC43 infections were positive by the recombinant\nSARS-CoV nucleocapsid protein-based ELISA for IgG anti-\nbody detection, with optical density at 450 nm (OD450) values\nof 0.337, 0.365, and 0.478 (Fig. 1). Although two serum samples\nproduced very faint bands in the recombinant SARS-CoV nu-\ncleocapsid protein-based Western blot assay, none of them\nwere found to contain the specific antibody by the recombinant\nSARS-CoV spike polypeptide-based Western blot assay (Fig.\n2). There was no relationship between the convalescent-phase\nsample titer or magnitude of the increase in the HCoV-OC43\nELISA and a positive result in the recombinant SARS-CoV\nnucleocapsid protein-based ELISA.\n\nOne of the seven convalescent-phase serum samples, but\nnone of the acute-phase serum samples, from patients with\nrecent HCoV-229E infection was positive by the recombinant\nSARS-CoV nucleocapsid protein-based ELISA for IgG detec-\ntion, with an OD450 value of 0.405 (Fig. 1). Although the serum\nsample produced a very faint band in the recombinant SARS-\nCoV nucleocapsid protein-based Western blot assay, it did not\ncontain the specific antibody according to the recombinant\nSARS-CoV spike polypeptide-based Western blot assay (Fig.\n2). The convalescent-phase serum positive in the recombinant\nSARS-CoV nucleocapsid protein-based ELISA was from the\nserum pair with the greatest rise in titer (eightfold) and had the\nhighest neutralizing-antibody titer.\n\nThe present study showed evidence that cross-reactivity in\n\nthe recombinant SARS-CoV nucleocapsid protein-based\nELISA between the SARS-CoV and serum samples positive\nfor antibodies against HCoV-229E or HCoV-OC43 is possible.\nIn our previous study on the optimization of the SARS-CoV\nrecombinant nucleocapsid protein-based ELISA for IgG anti-\nbody detection, seven of the serum samples obtained from 149\nhealthy blood donors who donated blood in 2000 had OD450s\ngreater than the cutoff value (15). However, none of them were\nfound to contain the specific antibody by both the nucleocapsid\nprotein- and spike polypeptide-based Western blot assays. Fur-\nthermore, when this ELISA was used to screen healthy blood\ndonors who donated blood during the SARS outbreak in Hong\nKong (March to May 2003), nonpneumonic hospitalized pa-\ntients, and asymptomatic health care workers, 33 (4%) of the\n828 serum samples screened were positive for IgG antibodies\n(15). However, only 4 (12%) of the 33 serum samples were\nconfirmed to contain specific SARS-CoV antibodies by both\nnucleocapsid protein- and spike polypeptide-based Western\nblot assays. We speculated that the false-positive results could\nbe due to cross-reactivity between the nucleocapsid protein of\nSARS-CoV and serum samples positive for antibodies against\nHCoV-229E, HCoV-OC43, or other undiscovered human\ncoronaviruses, as there is significant homology between the\nnucleocapsid protein of SARS-CoV and those of HCoV-OC43\nand HCoV-229E. In the present study, we showed that cross-\nreactivity between the nucleocapsid protein of SARS-CoV and\nserum samples positive for antibodies against HCoV-229E or\nHCoV-OC43 is indeed possible. For about 14% of the HCoV-\nOC43 and HCoV-229E infections detected by serum antibody\nincreases, an antibody increase was detected by the SARS-\nCoV nucleocapsid protein-based ELISA. The cross-reactive\nserum from an HCoV-229E infection had the highest conva-\nlescent-phase sample titer and greatest increase in titer, but no\nrelationship between the HCoV-OC43 ELISA titers and de-\ntection of antibody in the SARS-CoV nucleocapsid protein-\n\nFIG. 1. Recombinant SARS-CoV nucleocapsid protein-based IgG antibody ELISA for serum samples positive for the anti-HCoV-OC43 or\nanti-HCoV-229E antibody.\n\n5886 NOTES J. CLIN. MICROBIOL.\n\n\n\nbased ELISA was observed. Patients with a positive SARS-\nCoV nucleocapsid protein-based ELISA result tended to be\nyounger than those with negative tests, but clinical character-\nistics of the illnesses for these two groups were the same (data\nnot shown). For the two HCoV-OC43 antibody-positive serum\nsamples that produced bands when they were tested by the\nnucleocapsid protein-based Western blot assay, the bands were\nstronger than that produced by the HCoV-229E antibody-\npositive serum sample that tested positive by the nucleocapsid\nprotein-based ELISA (Fig. 2). This is probably because the\npercentage of amino acid identity between the nucleocapsid\nprotein of HCoV-OC43 and that of SARS-CoV (33%) is\nhigher than the amino acid identity between the nucleocapsid\nprotein of HCoV-OC43 and that of SARS-CoV (21%). Cross-\nreactivity with HCoV-OC43, HCoV-229E, and other corona-\nviruses remains an important issue for future studies on SARS-\nCoV serology. The use of synthetic peptides, instead of the\nwhole protein, for antibody detection could be a solution to\ncross-reactivity with proteins of other CoVs (13).\n\nThe present study confirmed the high specificity of the re-\ncombinant SARS-CoV nucleocapsid protein-based ELISA,\nwith positive results confirmed by Western blot assays using the\nrecombinant nucleocapsid protein and recombinant spike\npolypeptide of SARS-CoV. It is well known that, in the pres-\nence of possible cross-reactions, the positive predictive values\nof serological assays depend on the prevalence of the infection\nin a particular locality at a particular moment. In the present\nstudy the four false-positive results were rectified by consider-\ning Western blot positivity for both the recombinant nucleo-\ncapsid protein and spike polypeptide a genuinely positive re-\n\nsult. As the present ELISA produces a small proportion of\nfalse-positive reactions, all positive results, especially those\nobtained in the context of a low disease prevalence or from\nclinically incompatible cases, need confirmation by Western\nblot analysis using the recombinant nucleocapsid protein and\nspike polypeptide of SARS-CoV. Tan et al. recently demon-\nstrated the high sensitivity and specificity of recombinant nu-\ncleocapsid protein-based Western blot analysis and recombi-\nnant spike protein-based immunofluorescence assay for the\nserodiagnosis of SARS-CoV infection (12). As ELISA is less\nlabor-intensive and tedious to perform than Western blot as-\nsays, Western blot confirmation of positive ELISA results is\nprobably a better choice for routine use in clinical microbiol-\nogy laboratories. The Western blot assay for the spike polypep-\ntide may appear more specific than that for the nucleocapsid\nprotein because of possibly lower antibody titer of and/or avid-\nity for recombinant nonglycosylated protein. Further studies\ncould be performed to see whether Western blot analysis using\nonly the spike polypeptide, instead of using both the nucleo-\ncapsid protein and spike polypeptide, would be able to screen\nout all the false-positive results.\n\nThis study was supported by a Research Grant Council grant (HKU\n7532/03 M), the Research Fund for the Control of Infectious Diseases,\nthe Kai Cheong Tong SARS Research Fund, and NIH grant NO1-AI-\n65298 from the National Institute of Allergy and Infectious Diseases.\n\nREFERENCES\n\n1. Briese, T., C. G. Hatalski, S. Kliche, Y. S. Park, and W. I. Lipkin. 1995.\nEnzyme-linked immunosorbent assay for detecting antibodies to Borne dis-\nease virus-specific proteins. J. Clin. Microbiol. 33:348–351.\n\n2. Chan, C. M., P. C. Y. Woo, A. S. P. Leung, S. K. P. Lau, X. Y. Che, L. Cao,\n\nFIG. 2. Western blot analysis of purified recombinant SARS-CoV nucleocapsid protein (A) and spike polypeptide (B) using human sera that\ntested positive by the recombinant SARS-CoV nucleocapsid protein-based IgG antibody ELISA. Two of the three serum samples with the\nanti-HCoV-OC43 antibody (lanes 1 to 3) and the serum sample with the anti-HCoV-229E antibody (lanes 4) produced very faint bands in the\nrecombinant SARS-CoV nucleocapsid protein-based Western blot assay, but not the recombinant SARS-CoV spike polypeptide-based Western\nblot assays. Also shown are a positive control using serum of a patient with SARS-CoV pneumonia (lanes 5) and a negative control using serum\nof a healthy blood donor (lanes 6).\n\nVOL. 42, 2004 NOTES 5887\n\n\n\nand K. Y. Yuen. 2002. Detection of specific antibodies to an antigenic cell\nwall galactomannoprotein for serodiagnosis of Aspergillus fumigatus aspergil-\nlosis. J. Clin. Microbiol. 40:2041–2045.\n\n3. Chang, M. S., Y. T. Lu, S. T. Ho, C. C. Wu, T. Y. Wei, C. J. Chen, Y. T. Hsu,\nP. C. Chu, C. H. Chen, J. M. Chu, Y. L. Jan, C. C. Hung, C. C. Fan, and Y. C.\nYang. 2004. Antibody detection of SARS-CoV spike and nucleocapsid pro-\ntein. Biochem. Biophys. Res. Commun. 314:931–936.\n\n4. Chen, X., B. Zhou, M. Li, X. Liang, H. Wang, G. Yang, H. Wang, and X. Le.\n2004. Serology of severe acute respiratory syndrome: implications for sur-\nvival and outcome. J. Infect. Dis. 189:1158–1163.\n\n5. Frank, A. L., J. Puck, B. J. Hughes, and T. R. Cate. 1980. Microneutraliza-\ntion test for influenza A and B and parainfluenza 1 and 2 viruses that uses\ncontinuous cell lines and fresh serum enhancement. J. Clin. Microbiol. 12:\n426–432.\n\n6. Gill, E. P., E. A. Dominguez, S. B. Greenberg, R. L. Atmar, B. G. Hogue,\nB. D. Baxter, and R. B. Couch. 1994. Development and application of an\nenzyme immunoassay for coronavirus OC43 antibody in acute respiratory\nillness. J. Clin. Microbiol. 32:2372–2376.\n\n7. Guan, Y., B. J. Zheng, Y. Q. He, X. L. Liu, Z. X. Zhuang, C. L. Cheung, S. W.\nLuo, P. H. Li, L. J. Zhang, Y. J. Guan, K. M. Butt, K. L. Wong, K. W. Chan,\nW. Lim, K. F. Shortridge, K. Y. Yuen, J. S. Peiris, and L. L. Poon. 2003.\nIsolation and characterization of viruses related to the SARS coronavirus\nfrom animals in southern China. Science 302:276–278.\n\n8. Ksiazek, T. G., D. Erdman, C. S. Goldsmith, S. R. Zaki, T. Peret, S. Emery,\nS. Tong, C. Urbani, J. A. Comer, W. Lim, P. E. Rollin, S. F. Dowell, A. E.\nLing, C. D. Humphrey, W. J. Shieh, J. Guarner, C. D. Paddock, P. Rota, B.\nFields, J. DeRisi, J. Y. Yang, N. Cox, J. M. Hughes, J. W. LeDuc, W. J.\nBellini, L. J. Anderson, and the SARS Working Group. 2003. A novel\ncoronavirus associated with severe acute respiratory syndrome. N. Engl.\nJ. Med. 348:1953–1966.\n\n9. Peiris, J. S. M., C. M. Chu, V. C. C. Cheng, K. S. Chan, I. F. N. Hung,\nL. L. M. Poon, K. I. Law, B. S. F. Tang, T. Y. W. Hon, C. S. Chan, K. H.\nChan, J. S. C. Ng, B. J. Zheng, W. L. Ng, R. W. M. Lai, Y. Guan, K. Y. Yuen,\nand the HKU/UCH SARS Study Group. 2003. Clinical progression and viral\nload in a community outbreak of coronavirus-associated SARS pneumo-\nnia—a prospective study. Lancet 361:1767–1772.\n\n10. Peiris, J. S. M., S. T. Lai, L. L. M. Poon, Y. Guan, L. Y. C. Yam, W. Lim, J.\n\nNicholls, W. K. S. Yee, W. W. Yan, M. T. Cheung, V. C. C. Cheng, K. H.\nChan, D. N. C. Tsang, R. W. H. Yung, T. K. Ng, K. Y. Yuen, and the SARS\nStudy Group. 2003. Coronavirus as a possible cause of severe acute respi-\nratory syndrome. Lancet 361:1319–1325.\n\n11. Peiris, J. S. M., K. Y. Yuen, A. D. Osterhaus, and K. Stohr. 2003. The severe\nacute respiratory syndrome. N. Engl. J. Med. 349:2431–2441.\n\n12. Tan, Y. J., P. Y. Goh, B. C. Fielding, S. Shen, C. F. Chou, J. L. Fu, H. N.\nLeong, Y. S. Leo, E. E. Ooi, A. E. Ling, S. G. Lim, and W. Hong. 2004.\nProfiles of antibody responses against severe acute respiratory syndrome\ncoronavirus recombinant proteins and their potential use as diagnostic mark-\ners. Clin. Diagn. Lab. Immunol. 11:362–371.\n\n13. Wang, J., J. Wen, J. Li, J. Yin, Q. Zhu, H. Wang, Y. Yang, E. Qin, B. You, W.\nLi, X. Li, S. Huang, R. Yang, X. Zhang, L. Yang, T. Zhang, Y. Yin, X. Cui,\nX. Tang, L. Wang, B. He, L. Ma, T. Lei, C. Zeng, J. Fang, J. Yu, J. Wang, H.\nYang, M. B. West, A. Bhatnagar, Y. Lu, N. Xu, and S. Liu. 2003. Assessment\nof immunoreactive synthetic peptides from the structural proteins of severe\nacute respiratory syndrome coronavirus. Clin. Chem. 49:1989–1996.\n\n14. Woo, P. C. Y., K. T. K. Chong, A. S. P. Leung, S. S. Y. Wong, S. K. P. Lau,\nand K. Y. Yuen. 2003. AFLMP1 encodes an antigenic cell wall protein in\nAspergillus flavus. J. Clin. Microbiol. 41:845–850.\n\n15. Woo, P. C. Y., S. K. P. Lau, H. W. Tsoi, K. H. Chan, B. H. L. Wong, X. Y. Che,\nV. K. P. Tam, S. C. F. Tam, V. C. C. Cheng, I. F. N. Hung, S. S. Y. Wong, B. J.\nZheng, Y. Guan, and K. Y. Yuen. 2004. Relative rates of non-pneumonic\nSARS coronavirus infection and SARS coronavirus pneumonia. Lancet 363:\n841–845.\n\n16. Woo, P. C. Y., S. K. P. Lau, B. H. L. Wong, H. W. Tsoi, A. M. Y. Fung, K. H.\nChan, V. K. P. Tam, J. S. M. Peiris, and K. Y. Yuen. 2004. Detection of\nspecific antibodies to SARS coronavirus nucleocapsid protein for serodiag-\nnosis of SARS coronavirus pneumonia. J. Clin. Microbiol. 42:2306–2309.\n\n17. Wu, H. S., Y. C. Hsieh, I. J. Su, T. H. Lin, S. C. Chiu, Y. F. Hsu, J. H. Lin,\nM. C. Wang, J. Y. Chen, P. W. Hsiao, G. D. Chang, A. H. Wang, H. W. Ting,\nC. M. Chou, and C. J. Huang. 2004. Early detection of antibodies against\nvarious structural proteins of the SARS-associated coronavirus in SARS\npatients. J. Biomed. Sci. 11:117–126.\n\n18. Yuen, K. Y., C. M. Chan, K. M. Chan, P. C. Y. Woo, X. Y. Che, A. S. P. Leung,\nand L. Cao. 2001. Characterization of AFMP1: a novel target for serodiag-\nnosis of aspergillosis. J. Clin. Microbiol. 39:3830–3837.\n\n5888 NOTES J. CLIN. MICROBIOL.\n\nView publication statsView publication stats\n\nhttps://www.researchgate.net/publication/8145245\n\n'}